JHOP Articles

Skip to main content

Breast Cancer

Less Is More: Six Months of Traxtuzumab Equivalent to 12 Months in HER2-Positive Breast Cancer

Immunotherapy

Immunotherapy Combinations “Raising the Bar”

Screening

High Tumor Microsatellite Instability a Marker for Lynch Syndrome, More Common Condition Than Generally Expected

Breast Cancer

First-in-Class Antibody-Drug Conjugate Effective in HER2-Negative Metastatic Breast Cancer

Immunotherapy, Multiple Myeloma

Investigational CAR T-Cell Therapy, bb2121, Shows Durable Responses in Relapsed or Refractory Multiple Myeloma

Original Research

Retrospective Review of the Use of Oral Chemotherapy Drugs for Patients with Metastatic Renal-Cell Carcinoma

Nathan M. Kawamura, PharmD, BCOP, Sara Griesbach , PharmD, BCPS, BCACP, Sue Wilhelm, RPh, BCPS, Richard Mercier, MD

Original Research

Comparing Grade 4 Neutropenia Associated with Pegfilgrastim Administered via the Onpro Device versus Manual Injection with a Prefilled Syringe

Caroline Townley, PharmD, Courtney Porter, PharmD, BCOP, Nicole McMullen, PharmD, BCOP

Case Reports

Undetectable Everolimus Level from Probable Drug–Drug Interaction with Phenobarbital

Jaclynne Metayer, PharmD, Marina Rozov, PharmD, BCPS

Symptom Management Overview

Management of Rasburicase-Induced Hemolytic Anemia

David A. Kaland, PharmD, BCOP, Michelle A. Borg, PharmD

Ivosidenib a New Standard of Care for Relapsed or Refractory AML with IDH1 Mutation

Page 159 of 200
Results 1581 - 1590 of 1993